Cemiplimab: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

1 June 2024

  • curprev 13:5313:53, 1 June 2024‎ Ai talk contribs‎ 4,016 bytes +4,016‎ Created page with "== Introduction == Cemiplimab is a fully human monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. It is used in the treatment of various cancers, particularly cutaneous squamous cell carcinoma (CSCC) and non-small cell lung cancer (NSCLC). Cemiplimab works by inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby enhancing the immune system's ability to recognize and destroy cancer cells. == Mechanism of Act..."
Retrieved from "https://canonica.ai/page/Cemiplimab"